L
Lacy Sheets
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
Aug 18, 2026
Closing the Gap in Medical Necessity Review With a Clinical Documentation Integrity Registered Nurse
0:43
1:01
1:31
1:51
3:08
S
0:37Summer JohnsonHOST
Lacey Sheets is the Director of Financial Navigation and Financial Clearance at St. Luke's.

Lacy SheetsGUEST
So across oncology, I think in general, prior authorizations, medical necessity requirements, those things just continue to become more complex.

Lacy SheetsGUEST
So we were just finding that we were having more difficulties looking at that medical necessity review matching up those clinical criteria with those payers as well as having incomplete documentation within medical charts so we were trying to solve the problem of how do we navigate all of this so that we can have that Financial clearance happened for these patients prior to treatment.

Lacy SheetsGUEST
So that financial burden isn't something that they necessarily need to also be managing as they're managing their cancer diagnosis, as well as how are we relieving that from our providers and clinical teams, as well as those people who are not clinical, who are responsible for submitting the auth.

Lacy SheetsGUEST
So We really wanted to redesign the oncology financial clearance authorization process.

Lacy SheetsGUEST
Yeah, well, I'm hoping that the attendees, they'll leave with some strategies that they can implement themselves within their own organization, as well as to improve their own oncology financial clearance authorization process.